Clinical trial · Observational
A Comprehensive, Multinational GIST Registry
reGISTry - a Comprehensive, Multinational GIST Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients diagnosed with a gastrointestinal stromal tumor (GIST), a rare type of tumor in the digestive tractparticipate in this scientific research study, known as a registry study, to help improve understanding and treatment of GIST. This study collects medical information and biological samples-such as blood or tumor tissue-from patients. It does not involve new treatments, medications, or medical procedures. The patient's regular medical care will continue as usual, and participation will not require extra appointments or tests. The study aims to learn more about how GIST behaves, especially in rare forms such as SDH-deficient or NF1-associated tumors. While targeted drugs are available for many patients, some tumors return or become resistant to treatment. By gathering data from many patients, researchers hope to better understand these challenges, identify risk factors for worse outcomes, and help design future studies and treatments-especially for rare types of GIST. If the patient agrees to participate, information will be collected from their medical records, scans (such as CT or MRI), and doctor visits. They may be asked to complete optional questionnaires about their health and quality of life. If they consent, small blood samples (up to 50 ml) may be collected during routine check-ups. If surgery is needed, a small part of the tumor tissue may be stored for research. Other samples-such as saliva, stool, urine, or spinal fluid-may also be collected if they are taken during normal care, to study how bacteria in the body might affect the disease and treatment. Participation is completely voluntary. The patient can choose to join or not, and can withdraw at any time without affecting their care or relationship with their doctor. Even if they do not agree to provide biological samples, they can still take part in the study by sharing medical data and scan results.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointenstinal Stromal Tumor (GIST) | Gastrointestinal Stromal Tumor | ALIAS | 0.85 |
| GIST - Gastrointestinal Stromal Tumor | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- all patients with GIST regardless of disease status or molecular subtype
Primary outcomes (1)
- measure
- Creation of a prospective and retrospective, multi-center, international GIST cohort as a foundation for analyzing prognostic factors and planning future clinical trials.
- timeFrame
- 30 years
Secondary outcomes (4)
- measure
- Establishment of a comprehensive biobank with corresponding clinical, radiological, and histological data to support future research projects.
- timeFrame
- 30 years
- measure
- Identification of risk factors relevant to the treatment and counseling of GIST patients.
- timeFrame
- 30 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of a gastrointestinal stromal tumor (GIST) * Verbal and written informed consent for participation in the study with planned prospective data collection * Physical and mental ability to provide informed consent Exclusion Criteria: * Severe neurological or psychological illness that impairs the ability to give informed consent
References
Publications (0)
Data not yet available